by RJ Shara | Sep 13, 2021 | Startups
There are a growing number of companies interested in CRISPR’s possible to upend medication. It’s probably safe to say there’s just one company interested in utilizing the gene-editing system to produce a living, breathing woolly mammoth. Or, a minimum of, something pretty close to it. That’s the primary mission of a new business called Colossal. Co-founded […] It’s most likely safe to say there’s only one business interested in utilizing the gene-editing system to produce a living, breathing woolly massive. Lamm comes to Colossal as the founder of Hypergiant, a Texas-based AI business. The business’s pitch for bringing back the Mammoth, per the press release, is to fight the impacts of climate modification through community repair. 
…
by RJ Shara | Mar 8, 2021 | Startups
Antibiotic resistance is one of the biggest potential threats to global health today. But Locus Biosciences is hoping that their crPhage technology might provide a new solution. Based in North Carolina’s Research Triangle, the startup recently announced promising phase 1b clinical trial results for their use of CRISPR-Cas3-enhanced bacteriophages as a treatment for urinary tract […] …
by RJ Shara | Oct 6, 2020 | Startups
A brand-new company called Scribe Therapies founded by two previous members of CRISPR leader Jennifer Doudna’s UC Berkeley genes laboratory (alongside Doudna herself) released on Tuesday, debuting a platform developed specifically to assist establish and craft brand-new therapeutics based upon CRISPR for dealing with particular diseases, with long-term treatments in clients. Doudna becomes part of the […] Scribe has been at work on their service given that 2018, but remained mainly peaceful about their development until Oakes felt positive that what they’re providing is a genuine, viable technology that can be utilized to produce therapeutics now. Scribe will likewise be pursuing development of its own therapeutics in-house, while partnering where it makes sense– a strategy Oakes states is in service of dealing with the greatest number of possible illness treatments the start-up can manage. As for the basic science behind Scribe, their advantage lies in the work they have actually done to adapt a particle called CRISPR-CasX, which is a bit smaller than Cas9 and not derived from pathogen particles, both of which make it better-suited to therapies. …
by RJ Shara | Aug 13, 2020 | Startups
California-based start-up Mission Bio has raised a new$70 million Series C financing round, led by Novo Growth and including participation from Soleus Capital and existing investors Mayfield, Cota and Agilent. Objective Bio will use the funding to scale its Tapestri Platform, which uses the company’s work in single-cell multi-omics innovation to help enhance scientific […]…
by RJ Shara | Jul 31, 2020 | Startups
CRISPR tech startup Mammoth Biosciences is among the business that revealed backing from the National Institutes of Health (NIH) Fast Acceleration of Diagnostics (RADx) program on Friday. Massive got an agreement to scale up its CRISPR-based SARS-CoV-2 diagnostic test in order to assist deal with the screening scarcities throughout the U.S. Mammoth’s CRISPR-based technique might possibly […]…
by RJ Shara | Jul 2, 2020 | Startups
Jennifer Doudna, a female whose work has activated the surge in innovation in the field of artificial biology and has provided researchers all over the world a way to program and reprogram the living world, will be speaking at Disrupt in September. From her positions as the Chancellor’s Chair Teacher in the University of California, Berkeley’s […]
Pioneering CRISPR scientist Jennifer Doudna is coming to Interfere with …
by RJ Shara | Jun 14, 2020 | Startups
Bit Bio, the brand-new start-up that pitches itself as the “go into button for the keyboard to the software application of life,” just needed 3 weeks to raise its latest $41.5 million round of funding. Originally referred to as Elpis Biotechnology and named for the Greek goddess of hope, the Cambridge, England-based company was founded by Mark Kotter […] These cells can be utilized in targeted gene therapies and as a method to speed up drug discovery at pharmaceutical business. The company’s innovation has the possible to bring the long-awaited accuracy and reliability of engineering to the application of stem cells,” stated Klausner in a declaration. It was there that he started research structure on the innovative discoveries of Shinya Yamanaka, which enabled researchers to transform human adult cells into embryonic stem cells. The company is likewise preparing to develop its own cell therapies, according to Kotter. “If you look at these cell treatments at the minute you get mixed bags of cells….
by RJ Shara | Apr 16, 2020 | Startups
SF-based CRISPR diagnostics start-up Mammoth Biosciences has released the very first peer-reviewed research study that reveals recognition of using its testing method to find the existence of COVID-19 in patients. The research study,
released in Nature, shows efficiency on par with existing PCR-based molecular tests, the ones currently authorized for usage by the FDA to evaluate for the […]…
Recent Comments